Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Kidney Neoplasms 1 Carcinoma, Renal Cell 1

Interventions

pembrolizumab 304 Paclitaxel 206 Carboplatin 200 Gemcitabine 173 Cisplatin 139 Docetaxel 138 Cyclophosphamide 136 Nivolumab 129 Bevacizumab 118 Injections 111 fludarabine 96 atezolizumab 91 Pemetrexed 90 Dexamethasone 90 Cetuximab 90 Fluorouracil 84 Irinotecan 77 Rituximab 72 Capecitabine 72 venetoclax 71 Azacitidine 70 130-nm albumin-bound paclitaxel 67 Leucovorin 65 Fulvestrant 58 Oxaliplatin 57 durvalumab 56 Trastuzumab 56 Lenalidomide 55 Ipilimumab 55 Midazolam 54

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × INDUSTRY × PT2385 × Clear all

NCT02293980 2024-06-17

MK-3795-001

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1 Active not recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡